aluates Reports

$ 0.0

Automative

Global Anti-HER2 Therapy Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-32M13227

Global Anti HER2 Therapy Market Research Report 2023

BUY CHAPTERS

Global Anti-HER2 Therapy Market Research Report 2025

Code: QYRE-Auto-32M13227

Report

January 2025

Pages:95

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

GlaxoSmithKline PLC

Bayer

Abbott

AbbVie

Pfizer Inc

Sanofi

Merck

Glenmark Pharmaceuticals

Roche

Novartis

Astra Zeneca

Daiichi Sankyo

Celltrion

TEVA

Biocon Ltd.

Viatris

Anti-HER2 Therapy Market Size

The global market for Anti-HER2 Therapy was valued at US$ 5920 million in the year 2024 and is projected to reach a revised size of US$ 8022 million by 2031, growing at a CAGR of 4.5% during the forecast period.

Anti-HER2 Therapy Market

Anti-HER2 Therapy is a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.In HER2-positive breast cancer, the HER2 (human epidermal growth factor receptor 2) gene doesn’t work correctly and makes too many copies of itself. These extra HER2 genes make too many proteins known as HER2 receptors.Anti-HER2 medicines attach to the HER2 receptor proteins on the surface of breast cancer cells.Anti-HER2 medicines work by blocking the HER2 receptors from receiving the growth signals in HER2-positive breast cancer. By blocking the growth signals, anti-HER2 medicines can slow or stop the growth of HER2-positive and HER2-low breast cancer. Anti-HER2 medicines only work on HER2-positive and HER2-low breast cancer. They do not work on HER2-negative breast cancer.

The global anti-HER2 therapy market refers to the market for therapies targeting the human epidermal growth factor receptor 2 (HER2), which is a protein involved in the growth and spread of certain types of cancer. Anti-HER2 therapies are specifically designed to inhibit or block the activity of HER2, thereby slowing down or stopping the growth of cancer cells. These therapies have revolutionized the treatment of HER2-positive cancers, such as breast and gastric cancer, and have significantly improved patient outcomes.

Here are some key features and trends in the global anti-HER2 therapy market:

Increasing Incidence of HER2-Positive Cancers: The prevalence of HER2-positive cancers, especially breast cancer, is on the rise globally. HER2-positive breast cancer accounts for a significant proportion of breast cancer cases. As a result, there is a growing need for effective therapies that specifically target HER2 to improve patient outcomes and survival rates.

Targeted Therapies as Standard of Care: Anti-HER2 therapies, including monoclonal antibodies and small molecule inhibitors, have become the standard of care for the treatment of HER2-positive cancers. These therapies have demonstrated significant clinical benefits, such as improved progression-free survival and overall survival rates, compared to traditional chemotherapy regimens.

Monoclonal Antibodies: Monoclonal antibodies targeting HER2, such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), are widely used in the treatment of HER2-positive cancers. These antibodies specifically bind to HER2 receptors on cancer cells, blocking the signals that promote cell growth and proliferation. They may be used alone or in combination with other therapies to maximize efficacy.

Small Molecule Inhibitors: In addition to monoclonal antibodies, small molecule inhibitors targeting HER2, such as lapatinib and neratinib, have also been developed. These inhibitors work by blocking the intracellular signaling pathways involved in HER2-mediated cell growth and survival. Small molecule inhibitors are often used in combination with other targeted therapies or chemotherapy to enhance therapeutic efficacy.

Biomarker Testing: Accurate and reliable biomarker testing, such as HER2 testing, is essential for the selection of patients who will benefit from anti-HER2 therapies. HER2 testing helps identify patients with HER2-positive tumors, ensuring that they receive appropriate targeted treatments. Improvements in biomarker testing technologies and guidelines have contributed to better patient selection and treatment outcomes.

Combination Therapies: Combination therapies involving multiple anti-HER2 agents or the combination of anti-HER2 therapies with other targeted therapies or chemotherapy regimens are being explored. These combination approaches aim to further enhance the efficacy of anti-HER2 therapies and overcome resistance mechanisms that may develop over time.

Market Expansion and Access: Efforts are being made to improve patient access to anti-HER2 therapies globally. This includes initiatives to reduce treatment costs, expand market availability in underdeveloped regions, and facilitate regulatory approvals for these therapies. Increasing access to anti-HER2 therapies is crucial to ensure that patients in all regions can benefit from these advanced treatment options.

In conclusion, the global anti-HER2 therapy market is driven by the increasing incidence of HER2-positive cancers and the clinical benefits offered by targeted therapies. Monoclonal antibodies and small molecule inhibitors targeting HER2 have become the standard of care for HER2-positive cancers, providing improved patient outcomes. Biomarker testing plays a crucial role in patient selection, and combination therapies are being explored to enhance efficacy. With a competitive market landscape and efforts to improve market access, the global anti-HER2 therapy market is expected to continue expanding to meet the growing demand for targeted treatments in HER2-positive cancers.The global anti-HER2 therapy market refers to the market for therapies targeting the human epidermal growth factor receptor 2 (HER2), which is a protein involved in the growth and spread of certain types of cancer. Anti-HER2 therapies are specifically designed to inhibit or block the activity of HER2, thereby slowing down or stopping the growth of cancer cells. These therapies have revolutionized the treatment of HER2-positive cancers, such as breast and gastric cancer, and have significantly improved patient outcomes.

Here are some key features and trends in the global anti-HER2 therapy market:

This report aims to provide a comprehensive presentation of the global market for Anti-HER2 Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-HER2 Therapy.

The Anti-HER2 Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-HER2 Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anti-HER2 Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Anti-HER2 Therapy Market Report

Report Metric	Details
Report Name	Anti-HER2 Therapy Market
Accounted market size in year	US$ 5920 million
Forecasted market size in 2031	US$ 8022 million
CAGR	4.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Anti-HER2 Monoclonal Antibodies Antibody-Drug Conjugate Kinase Inhibitors
Segment by Application	Online Pharmacy Retail Pharmacy Medical Clinics
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GlaxoSmithKline, Bayer, Abbott, AbbVie, Pfizer, Sanofi, Merck, Glenmark Pharmaceuticals, Roche, Novartis, Astra Zeneca, Daiichi Sankyo, Celltrion, Teva, Biocon, Viatris
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-HER2 Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Anti-HER2 Therapy Market growing?

Ans: The Anti-HER2 Therapy Market witnessing a CAGR of 4.5% during the forecast period 2025-2031.

What is the Anti-HER2 Therapy Market size in 2031?

Ans: The Anti-HER2 Therapy Market size in 2031 will be US$ 8022 million.

Who are the main players in the Anti-HER2 Therapy Market report?

Ans: The main players in the Anti-HER2 Therapy Market are GlaxoSmithKline, Bayer, Abbott, AbbVie, Pfizer, Sanofi, Merck, Glenmark Pharmaceuticals, Roche, Novartis, Astra Zeneca, Daiichi Sankyo, Celltrion, Teva, Biocon, Viatris

What are the Application segmentation covered in the Anti-HER2 Therapy Market report?

Ans: The Applications covered in the Anti-HER2 Therapy Market report are Online Pharmacy, Retail Pharmacy, Medical Clinics

What are the Type segmentation covered in the Anti-HER2 Therapy Market report?

Ans: The Types covered in the Anti-HER2 Therapy Market report are Anti-HER2 Monoclonal Antibodies, Antibody-Drug Conjugate, Kinase Inhibitors

Recommended Reports

Targeted Cancer Therapies

Breast Cancer Markets

Cancer Drug Classes

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Anti-HER2 Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Anti-HER2 Monoclonal Antibodies

1.2.3 Antibody-Drug Conjugate

1.2.4 Kinase Inhibitors

1.3 Market by Application

1.3.1 Global Anti-HER2 Therapy Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Online Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Medical Clinics

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Anti-HER2 Therapy Market Perspective (2020-2031)

2.2 Global Anti-HER2 Therapy Growth Trends by Region

2.2.1 Global Anti-HER2 Therapy Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Anti-HER2 Therapy Historic Market Size by Region (2020-2025)

2.2.3 Anti-HER2 Therapy Forecasted Market Size by Region (2026-2031)

2.3 Anti-HER2 Therapy Market Dynamics

2.3.1 Anti-HER2 Therapy Industry Trends

2.3.2 Anti-HER2 Therapy Market Drivers

2.3.3 Anti-HER2 Therapy Market Challenges

2.3.4 Anti-HER2 Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Anti-HER2 Therapy Players by Revenue

3.1.1 Global Top Anti-HER2 Therapy Players by Revenue (2020-2025)

3.1.2 Global Anti-HER2 Therapy Revenue Market Share by Players (2020-2025)

3.2 Global Anti-HER2 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Anti-HER2 Therapy Revenue

3.4 Global Anti-HER2 Therapy Market Concentration Ratio

3.4.1 Global Anti-HER2 Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Anti-HER2 Therapy Revenue in 2024

3.5 Global Key Players of Anti-HER2 Therapy Head office and Area Served

3.6 Global Key Players of Anti-HER2 Therapy, Product and Application

3.7 Global Key Players of Anti-HER2 Therapy, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-HER2 Therapy Breakdown Data by Type

4.1 Global Anti-HER2 Therapy Historic Market Size by Type (2020-2025)

4.2 Global Anti-HER2 Therapy Forecasted Market Size by Type (2026-2031)

5 Anti-HER2 Therapy Breakdown Data by Application

5.1 Global Anti-HER2 Therapy Historic Market Size by Application (2020-2025)

5.2 Global Anti-HER2 Therapy Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Anti-HER2 Therapy Market Size (2020-2031)

6.2 North America Anti-HER2 Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Anti-HER2 Therapy Market Size by Country (2020-2025)

6.4 North America Anti-HER2 Therapy Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Anti-HER2 Therapy Market Size (2020-2031)

7.2 Europe Anti-HER2 Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Anti-HER2 Therapy Market Size by Country (2020-2025)

7.4 Europe Anti-HER2 Therapy Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Anti-HER2 Therapy Market Size (2020-2031)

8.2 Asia-Pacific Anti-HER2 Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Anti-HER2 Therapy Market Size by Region (2020-2025)

8.4 Asia-Pacific Anti-HER2 Therapy Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Anti-HER2 Therapy Market Size (2020-2031)

9.2 Latin America Anti-HER2 Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Anti-HER2 Therapy Market Size by Country (2020-2025)

9.4 Latin America Anti-HER2 Therapy Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Anti-HER2 Therapy Market Size (2020-2031)

10.2 Middle East & Africa Anti-HER2 Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Anti-HER2 Therapy Market Size by Country (2020-2025)

10.4 Middle East & Africa Anti-HER2 Therapy Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GlaxoSmithKline

11.1.1 GlaxoSmithKline Company Details

11.1.2 GlaxoSmithKline Business Overview

11.1.3 GlaxoSmithKline Anti-HER2 Therapy Introduction

11.1.4 GlaxoSmithKline Revenue in Anti-HER2 Therapy Business (2020-2025)

11.1.5 GlaxoSmithKline Recent Development

11.2 Bayer

11.2.1 Bayer Company Details

11.2.2 Bayer Business Overview

11.2.3 Bayer Anti-HER2 Therapy Introduction

11.2.4 Bayer Revenue in Anti-HER2 Therapy Business (2020-2025)

11.2.5 Bayer Recent Development

11.3 Abbott

11.3.1 Abbott Company Details

11.3.2 Abbott Business Overview

11.3.3 Abbott Anti-HER2 Therapy Introduction

11.3.4 Abbott Revenue in Anti-HER2 Therapy Business (2020-2025)

11.3.5 Abbott Recent Development

11.4 AbbVie

11.4.1 AbbVie Company Details

11.4.2 AbbVie Business Overview

11.4.3 AbbVie Anti-HER2 Therapy Introduction

11.4.4 AbbVie Revenue in Anti-HER2 Therapy Business (2020-2025)

11.4.5 AbbVie Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Anti-HER2 Therapy Introduction

11.5.4 Pfizer Revenue in Anti-HER2 Therapy Business (2020-2025)

11.5.5 Pfizer Recent Development

11.6 Sanofi

11.6.1 Sanofi Company Details

11.6.2 Sanofi Business Overview

11.6.3 Sanofi Anti-HER2 Therapy Introduction

11.6.4 Sanofi Revenue in Anti-HER2 Therapy Business (2020-2025)

11.6.5 Sanofi Recent Development

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Anti-HER2 Therapy Introduction

11.7.4 Merck Revenue in Anti-HER2 Therapy Business (2020-2025)

11.7.5 Merck Recent Development

11.8 Glenmark Pharmaceuticals

11.8.1 Glenmark Pharmaceuticals Company Details

11.8.2 Glenmark Pharmaceuticals Business Overview

11.8.3 Glenmark Pharmaceuticals Anti-HER2 Therapy Introduction

11.8.4 Glenmark Pharmaceuticals Revenue in Anti-HER2 Therapy Business (2020-2025)

11.8.5 Glenmark Pharmaceuticals Recent Development

11.9 Roche

11.9.1 Roche Company Details

11.9.2 Roche Business Overview

11.9.3 Roche Anti-HER2 Therapy Introduction

11.9.4 Roche Revenue in Anti-HER2 Therapy Business (2020-2025)

11.9.5 Roche Recent Development

11.10 Novartis

11.10.1 Novartis Company Details

11.10.2 Novartis Business Overview

11.10.3 Novartis Anti-HER2 Therapy Introduction

11.10.4 Novartis Revenue in Anti-HER2 Therapy Business (2020-2025)

11.10.5 Novartis Recent Development

11.11 Astra Zeneca

11.11.1 Astra Zeneca Company Details

11.11.2 Astra Zeneca Business Overview

11.11.3 Astra Zeneca Anti-HER2 Therapy Introduction

11.11.4 Astra Zeneca Revenue in Anti-HER2 Therapy Business (2020-2025)

11.11.5 Astra Zeneca Recent Development

11.12 Daiichi Sankyo

11.12.1 Daiichi Sankyo Company Details

11.12.2 Daiichi Sankyo Business Overview

11.12.3 Daiichi Sankyo Anti-HER2 Therapy Introduction

11.12.4 Daiichi Sankyo Revenue in Anti-HER2 Therapy Business (2020-2025)

11.12.5 Daiichi Sankyo Recent Development

11.13 Celltrion

11.13.1 Celltrion Company Details

11.13.2 Celltrion Business Overview

11.13.3 Celltrion Anti-HER2 Therapy Introduction

11.13.4 Celltrion Revenue in Anti-HER2 Therapy Business (2020-2025)

11.13.5 Celltrion Recent Development

11.14 Teva

11.14.1 Teva Company Details

11.14.2 Teva Business Overview

11.14.3 Teva Anti-HER2 Therapy Introduction

11.14.4 Teva Revenue in Anti-HER2 Therapy Business (2020-2025)

11.14.5 Teva Recent Development

11.15 Biocon

11.15.1 Biocon Company Details

11.15.2 Biocon Business Overview

11.15.3 Biocon Anti-HER2 Therapy Introduction

11.15.4 Biocon Revenue in Anti-HER2 Therapy Business (2020-2025)

11.15.5 Biocon Recent Development

11.16 Viatris

11.16.1 Viatris Company Details

11.16.2 Viatris Business Overview

11.16.3 Viatris Anti-HER2 Therapy Introduction

11.16.4 Viatris Revenue in Anti-HER2 Therapy Business (2020-2025)

11.16.5 Viatris Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

GlaxoSmithKline PLC

Bayer

Abbott

AbbVie

Pfizer Inc

Sanofi

Merck

Glenmark Pharmaceuticals

Roche

Novartis

Astra Zeneca

Daiichi Sankyo

Celltrion

TEVA

Biocon Ltd.

Viatris

List of Tables

Table 1. Global Anti-HER2 Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Anti-HER2 Monoclonal Antibodies

Table 3. Key Players of Antibody-Drug Conjugate

Table 4. Key Players of Kinase Inhibitors

Table 5. Global Anti-HER2 Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Anti-HER2 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Anti-HER2 Therapy Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Anti-HER2 Therapy Market Share by Region (2020-2025)

Table 9. Global Anti-HER2 Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Anti-HER2 Therapy Market Share by Region (2026-2031)

Table 11. Anti-HER2 Therapy Market Trends

Table 12. Anti-HER2 Therapy Market Drivers

Table 13. Anti-HER2 Therapy Market Challenges

Table 14. Anti-HER2 Therapy Market Restraints

Table 15. Global Anti-HER2 Therapy Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Anti-HER2 Therapy Market Share by Players (2020-2025)

Table 17. Global Top Anti-HER2 Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-HER2 Therapy as of 2024)

Table 18. Ranking of Global Top Anti-HER2 Therapy Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Anti-HER2 Therapy Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Anti-HER2 Therapy, Headquarters and Area Served

Table 21. Global Key Players of Anti-HER2 Therapy, Product and Application

Table 22. Global Key Players of Anti-HER2 Therapy, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Anti-HER2 Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Anti-HER2 Therapy Revenue Market Share by Type (2020-2025)

Table 26. Global Anti-HER2 Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Anti-HER2 Therapy Revenue Market Share by Type (2026-2031)

Table 28. Global Anti-HER2 Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Anti-HER2 Therapy Revenue Market Share by Application (2020-2025)

Table 30. Global Anti-HER2 Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Anti-HER2 Therapy Revenue Market Share by Application (2026-2031)

Table 32. North America Anti-HER2 Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Anti-HER2 Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Anti-HER2 Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Anti-HER2 Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Anti-HER2 Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Anti-HER2 Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Anti-HER2 Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Anti-HER2 Therapy Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Anti-HER2 Therapy Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Anti-HER2 Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Anti-HER2 Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Anti-HER2 Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Anti-HER2 Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Anti-HER2 Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Anti-HER2 Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 47. GlaxoSmithKline Company Details

Table 48. GlaxoSmithKline Business Overview

Table 49. GlaxoSmithKline Anti-HER2 Therapy Product

Table 50. GlaxoSmithKline Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 51. GlaxoSmithKline Recent Development

Table 52. Bayer Company Details

Table 53. Bayer Business Overview

Table 54. Bayer Anti-HER2 Therapy Product

Table 55. Bayer Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 56. Bayer Recent Development

Table 57. Abbott Company Details

Table 58. Abbott Business Overview

Table 59. Abbott Anti-HER2 Therapy Product

Table 60. Abbott Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 61. Abbott Recent Development

Table 62. AbbVie Company Details

Table 63. AbbVie Business Overview

Table 64. AbbVie Anti-HER2 Therapy Product

Table 65. AbbVie Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 66. AbbVie Recent Development

Table 67. Pfizer Company Details

Table 68. Pfizer Business Overview

Table 69. Pfizer Anti-HER2 Therapy Product

Table 70. Pfizer Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 71. Pfizer Recent Development

Table 72. Sanofi Company Details

Table 73. Sanofi Business Overview

Table 74. Sanofi Anti-HER2 Therapy Product

Table 75. Sanofi Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 76. Sanofi Recent Development

Table 77. Merck Company Details

Table 78. Merck Business Overview

Table 79. Merck Anti-HER2 Therapy Product

Table 80. Merck Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 81. Merck Recent Development

Table 82. Glenmark Pharmaceuticals Company Details

Table 83. Glenmark Pharmaceuticals Business Overview

Table 84. Glenmark Pharmaceuticals Anti-HER2 Therapy Product

Table 85. Glenmark Pharmaceuticals Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 86. Glenmark Pharmaceuticals Recent Development

Table 87. Roche Company Details

Table 88. Roche Business Overview

Table 89. Roche Anti-HER2 Therapy Product

Table 90. Roche Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 91. Roche Recent Development

Table 92. Novartis Company Details

Table 93. Novartis Business Overview

Table 94. Novartis Anti-HER2 Therapy Product

Table 95. Novartis Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 96. Novartis Recent Development

Table 97. Astra Zeneca Company Details

Table 98. Astra Zeneca Business Overview

Table 99. Astra Zeneca Anti-HER2 Therapy Product

Table 100. Astra Zeneca Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 101. Astra Zeneca Recent Development

Table 102. Daiichi Sankyo Company Details

Table 103. Daiichi Sankyo Business Overview

Table 104. Daiichi Sankyo Anti-HER2 Therapy Product

Table 105. Daiichi Sankyo Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 106. Daiichi Sankyo Recent Development

Table 107. Celltrion Company Details

Table 108. Celltrion Business Overview

Table 109. Celltrion Anti-HER2 Therapy Product

Table 110. Celltrion Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 111. Celltrion Recent Development

Table 112. Teva Company Details

Table 113. Teva Business Overview

Table 114. Teva Anti-HER2 Therapy Product

Table 115. Teva Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 116. Teva Recent Development

Table 117. Biocon Company Details

Table 118. Biocon Business Overview

Table 119. Biocon Anti-HER2 Therapy Product

Table 120. Biocon Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 121. Biocon Recent Development

Table 122. Viatris Company Details

Table 123. Viatris Business Overview

Table 124. Viatris Anti-HER2 Therapy Product

Table 125. Viatris Revenue in Anti-HER2 Therapy Business (2020-2025) & (US$ Million)

Table 126. Viatris Recent Development

Table 127. Research Programs/Design for This Report

Table 128. Key Data Information from Secondary Sources

Table 129. Key Data Information from Primary Sources

Table 130. Authors List of This Report

List of Figures

Figure 1. Anti-HER2 Therapy Picture

Figure 2. Global Anti-HER2 Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Anti-HER2 Therapy Market Share by Type: 2024 VS 2031

Figure 4. Anti-HER2 Monoclonal Antibodies Features

Figure 5. Antibody-Drug Conjugate Features

Figure 6. Kinase Inhibitors Features

Figure 7. Global Anti-HER2 Therapy Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Anti-HER2 Therapy Market Share by Application: 2024 VS 2031

Figure 9. Online Pharmacy Case Studies

Figure 10. Retail Pharmacy Case Studies

Figure 11. Medical Clinics Case Studies

Figure 12. Anti-HER2 Therapy Report Years Considered

Figure 13. Global Anti-HER2 Therapy Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Anti-HER2 Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Anti-HER2 Therapy Market Share by Region: 2024 VS 2031

Figure 16. Global Anti-HER2 Therapy Market Share by Players in 2024

Figure 17. Global Top Anti-HER2 Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-HER2 Therapy as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Anti-HER2 Therapy Revenue in 2024

Figure 19. North America Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Anti-HER2 Therapy Market Share by Country (2020-2031)

Figure 21. United States Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Anti-HER2 Therapy Market Share by Country (2020-2031)

Figure 25. Germany Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Anti-HER2 Therapy Market Share by Region (2020-2031)

Figure 33. China Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Anti-HER2 Therapy Market Share by Country (2020-2031)

Figure 41. Mexico Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Anti-HER2 Therapy Market Share by Country (2020-2031)

Figure 45. Turkey Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Anti-HER2 Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. GlaxoSmithKline Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 49. Bayer Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 50. Abbott Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 51. AbbVie Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 52. Pfizer Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 53. Sanofi Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 54. Merck Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 55. Glenmark Pharmaceuticals Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 56. Roche Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 57. Novartis Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 58. Astra Zeneca Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 59. Daiichi Sankyo Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 60. Celltrion Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 61. Teva Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 62. Biocon Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 63. Viatris Revenue Growth Rate in Anti-HER2 Therapy Business (2020-2025)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global HER2 Antibody Market Research Report 2025

Global Herceptin Trastuzumab Market Research Report 2024

Global HER2 Antibody Drug Conjugate Market Research Report 2025

Global Epidermal Growth Factor Receptor Inhibitors Market Research Report 2024

Global Anticancer Drugs Market Research Report 2025

Global Mono Antibody mAb for HER2 Positive Advanced Breast Cancer Market Research Report 2024

Global HER2 Human Epidermal Growth Factor Receptor 2 Antibody Market Research Report 2024

Global HER2 Inhibitors Market Research Report 2024

Global ALK Inhibitors Market Research Report 2024

Global HER2 Targeted Therapy Market Research Report 2024

Global Anti VEGF Drugs for Angiogenesis related Disease Market Research Report 2024

Global Epidermal Growth Factor Receptor EGFR Inhibitor Market Insights Forecast to 2030

Global HER2 Positive Breast Cancer Market Research Report 2024

Global Anti VEGF Therapy for Cancer Market Research Report 2024

Global HER2 Target Drugs Market Research Report 2024

Trastuzumab Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Kinase Inhibitors For Cancer Treatment Market Research Report 2024

Global Anti Vascular Endothelial Growth Factor Therapeutic Market Research Report 2025

Global Anti VEGF Therapeutic Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions